Doripenem Dosing Recommendations for Critically Ill Patients Receiving Continuous Renal Replacement Therapy

Table 1

Results of nonparametric superposition and noncompartmental analysis performed on mean data for doripenem and doripenem-M-1.


	Continuous venovenous hemofiltration				Continuous venovenous hemodiafiltration					Healthy subjects^a
	Day 1^a	Simulated steady-state (day 10)			Day 1^a	Simulated steady-state (day 10)
	500 mg q12h	500 mg q8h	250 mg q8h	250 mg q12h	500 mg q12h	500 mg q8h	375 mg q12h	250 mg q8h	250 mg q12h	1000 mg q8h

Doripenem
(mg/L)	24.1	29.6	14.9	13.2	22.5	26.5	17.9	13.2	12.0	44.0
(mgh/L)	97.6	114	57.1	57.1	88.4	86.5	64.9	43.3	43.3	69.6
AUC_24,ss (mgh/L)	N/A	342.0	171.3	114.2	N/A	259.5	129.8	129.9	86.6	208.8
Doripenem-M-1
(mg/L)	3.02	8.86	4.44	3.27	3.66	9.15	5.23	4.57	3.49	9.81
(mgh/L)	24.4	58.6	29.3	29.3	21.8	54.2	40.7	27.1	27.1	21.3
AUC_24,ss (mgh/L)	N/A	175.8	87.9	58.6	N/A	162.6	81.4	81.3	54.2	63.9

AUC_24,ss: total daily area under the curve at steady state; : area under the curve at steady state during the dosing interval ; : maximum plasma concentration at steady state; q8h: every 8 hours; q12h: every 12 hours.
The day 1 500 mg q12h CRRT data and the healthy subject data are observed results from single- and multiple dose studies. All doripenem dosing regimens were a 1-hour infusion duration.

International Scholarly Research Notices

Doripenem Dosing Recommendations for Critically Ill Patients Receiving Continuous Renal Replacement Therapy

Table 1